Table 3.
Comperative demographic characteristics
| Researchers | Patients (n) | Median follow-up (Months) | Disease Progression (%) | Survival rates (%) | RP (%) performed upon patient’s request | Patients (n) remaining on active surveillance (PFS) (%) | ||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| Biopsy | PSA DT | OS | CSS | |||||
| Klotz et al.[6] | 453 | 82 | 9 | 14 | 78.6 | 97.2 | 3 | 70 |
|
| ||||||||
| Dall’Era et al.[7] | 321 | 47 | 35 | 5 | 97 | 100 | 8 | 54 |
|
| ||||||||
| Van As et al.[8] | 326 | 22 | 13 | 18 | 98 | 100 | 2 | 73 |
|
| ||||||||
| Soloway et al.[9] | 230 | 32 | 10 | - | 100 | 100 | - | 86 |
|
| ||||||||
| Our study | 43 | 42 | 16 | - | 97.6 | 100 | 4.6 | 77 |
OS: overall survival; CSS: cancer-specific survival; PFS: progression-free survival